Roivant Sciences Ltd. (NASDAQ: ROIV) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
Latest market price
34.59
+1.27+3.81%
Earnings
Up 3.8% — Earnings due 2026-08-06 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | - | P/E | - | EPS (ttm) | -0.51 | Insider Own | 23.16% | Shs Outstand | 722.41M | Perf Week | 2.22% |
| Market Cap | 24.99B | Forward P/E | - | EPS next Y | -1.04 | Insider Trans | -8.47% | Shs Float | 519.88M | Perf Month | -2.26% |
| Enterprise Value | 20.80B | PEG | - | EPS next Q | - | Inst Own | - | Short Float | 7.06% | Perf Quarter | 21.97% |
| Income | -300.00M | P/S | - | EPS this Y | -145.69% | Inst Trans | - | Short Ratio | 6.13 | Perf Half Y | 57.66% |
| Sales | 9.00M | P/B | 4.72 | EPS next Y | 16.96% | ROA | -5.23% | Short Interest | 36.70M | Perf YTD | 59.40% |
| Book/sh | 7.33 | P/C | 5.82 | EPS next 5Y | - | ROE | -6.85% | 52W High | 37.00 -6.51% | Perf Year | 205.84% |
| Cash/sh | 5.95 | P/FCF | - | EPS past 3/5Y | - | ROIC | -23.55% | 52W Low | 10.90 217.34% | Perf 3Y | 196.66% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -37.00% -19.73% | Gross Margin | 84.44% | Volatility | 3.67% 3.30% | Perf 5Y | 249.04% |
| Dividend TTM | - | EV/Sales | - | EPS Y/Y TTM | -112.50% | Oper. Margin | -15560.57% | ATR (14) | 1.21 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 18.37 | Sales Y/Y TTM | -68.97% | Profit Margin | -3629.19% | RSI (14) | 53.55 | Recom | 2.07 |
| Dividend Gr. 3/5Y | - | Current Ratio | 18.37 | EPS Q/Q | 3.72% | SMA20 | -0.23% | Beta | 1.09 | Target Price | 37.17 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | -62.50% | SMA50 | 5.91% | Rel Volume | 1.01 | Prev Close | 33.32 |
| Employees | 721 | LT Debt/Eq | 0.02 | Earnings | Aug 06 | SMA200 | 30.06% | Avg Volume | 5.82M | Price | 34.59 |
| IPO Date | Dec 08, 2020 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 3.49% -26.20% | Net Debt/EBITDA | 5.04 | Volume | 5,880,072 | Change | 3.81% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| May-26-26 | Reiterated | Guggenheim | Buy | $30 → $36 |
| May-21-26 | Reiterated | Cowen & Co. | Outperform | $38 → $41 |
| May-21-26 | Reiterated | Leerink Partners | Outperform | $32 → $42 |
| Apr-16-26 | Reiterated | Piper Sandler | Overweight | $20 → $40 |
| Mar-04-26 | Reiterated | HC Wainwright & Co. | Buy | $33 → $34 |
| Feb-10-26 | Reiterated | HC Wainwright & Co. | Buy | $26 → $33 |
| Feb-09-26 | Reiterated | Jefferies | Buy | $24 → $30 |
| Feb-09-26 | Reiterated | Guggenheim | Buy | $28 → $30 |
| Dec-18-25 | Reiterated | Guggenheim | Buy | $25 → $28 |
| Dec-15-25 | Reiterated | Leerink Partners | Outperform | $29 → $32 |
Latest News
Aug-04-26
Aug-04-2604:47AM
Jul-29-26
Jul-25-26
04:21AM
Jul-23-26
Jul-23-2608:05PM
04:05PM
Jul-16-26
Jul-07-26
Jun-30-26
Jun-25-26
Jun-17-26
Jun-17-2601:46PM
Jun-11-26
Jun-11-2601:00AM
Jun-09-26
Jun-09-2608:22PM
Company
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 3/31/2026 | FY 2024 3/31/2025 | FY 2023 3/31/2024 | FY 2022 3/31/2023 | FY 2021 3/31/2022 | FY 2020 3/31/2021 | FY 2019 3/31/2020 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 9 | 8 | 29 | 33 | 32 | 55 | 24 | 68 | |
| Cost of Goods Sold Incl. D&A | 1 | 1 | 1 | 2 | 3 | 9 | 2 | 1 | |
| Gross Profit | 6 | 7 | 28 | 31 | 28 | 46 | 22 | 67 | |
| Selling, General and Administrative Excl. Other | 610 | 610 | 591 | 416 | 383 | 775 | 260 | 336 | |
| Research and Development | 682 | 682 | 550 | 440 | 454 | 483 | 237 | 263 | |
| Other Operating Expense | 0 | 0 | 1 | 0 | 1 | 0 | 596 | 0 | |
| Operating Income | -1,285 | -1,285 | -1,114 | -825 | -809 | -1,212 | -1,071 | -532 | |
| Interest Expense | 0 | 0 | 0 | 35 | 28 | 7 | 3 | 8 | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1,021 | 1,021 | 432 | 5,428 | -48 | 295 | 175 | -21 | |
| Net Income Before Taxes | -264 | -265 | -682 | 4,568 | -885 | -924 | -899 | -561 | |
| Income Taxes | 133 | 133 | 48 | 22 | 4 | 0 | 2 | 7 | |
| Consolidated Net Income | -300 | -300 | -172 | 4,349 | -1,009 | -845 | -809 | 1,201 | |
| Net Income From Continuing Operations | -398 | -398 | -730 | 4,546 | -889 | -924 | -900 | -568 | |
| Net Income | -300 | -300 | -172 | 4,349 | -1,009 | -845 | -809 | 1,201 | |
| EPS (Recurring) | -0.45 | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | -1.18 | 1.75 | |
| EPS (Basic, Before Extraordinaries) | -0.45 | -0.43 | -0.24 | 5.55 | -1.42 | -1.26 | -1.18 | 1.75 | |
| EPS (Diluted) | -0.51 | -0.43 | -0.24 | 5.23 | -1.42 | -1.26 | -1.18 | 1.75 | |
| EBITDA | -261 | -261 | -668 | 4,625 | -838 | -911 | -896 | -553 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | 2.02 | — | — | — | — | |
| Price To Sales Ratio | 2,698.02 | 2,402.98 | 252.25 | 250.09 | 164.44 | 60.18 | 279.14 | — | |
| Gross Margin | 66.67 | 87.50 | 96.55 | 93.94 | 87.50 | 83.64 | 91.67 | 98.53 | |
| Operating Margin | -14,277.78 | -16,062.50 | -3,841.38 | -2,500.00 | -2,528.13 | -2,203.64 | -4,462.50 | -782.35 | |
| Net Margin | -3,333.33 | -3,750.00 | -593.10 | 13,178.79 | -3,153.13 | -1,536.36 | -3,370.83 | 1,766.18 | |
| Shares Outstanding | 702 | 694 | 725 | 783 | 713 | 670 | 685 | 685 | |
| Market Capitalization | 24,282 | 19,224 | 7,315 | 8,253 | 5,262 | 3,310 | 6,699 | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Venker Eric | President & Immunovant CEO | Jul 27 '26 | Option Exercise | 3.85 | 200,000 | 770,000 | 1,813,063 | Jul 29 |
| Venker Eric | President & Immunovant CEO | Jul 27 '26 | Sale | 34.95 | 200,000 | 6,990,000 | 1,613,063 | Jul 29 |
| Fitzgerald Meghan | Director | Jun 30 '26 | Option Exercise | 8.80 | 10,000 | 88,000 | 52,963 | Jul 02 |
| Fitzgerald Meghan | Director | Jun 30 '26 | Sale | 34.90 | 10,000 | 349,000 | 42,963 | Jul 02 |
| Epperly Melissa B, | Director | Jun 29 '26 | Option Exercise | 4.46 | 17,750 | 79,165 | 34,224 | Jul 01 |
| Epperly Melissa B, | Director | Jun 29 '26 | Sale | 34.38 | 17,750 | 610,252 | 16,474 | Jul 01 |
| Gold Daniel Allen | Director | Jun 30 '26 | Sale | 35.28 | 12,380 | 436,766 | 13,689,166 | Jun 30 |
| QVT Financial LP | other: Director by Deputization | Jun 30 '26 | Sale | 35.28 | 12,380 | 436,766 | 13,689,166 | Jun 30 |
| MANCHESTER KEITH S | Director | Jun 30 '26 | Sale | 35.44 | 212,380 | 7,526,766 | 1,748,403 | Jun 30 |
| Gold Daniel Allen | Director | Jun 29 '26 | Sale | 34.55 | 800,000 | 27,642,000 | 13,701,546 | Jun 30 |
| QVT Financial LP | other: Director by Deputization | Jun 29 '26 | Sale | 34.55 | 800,000 | 27,642,000 | 13,701,546 | Jun 30 |
| MANCHESTER KEITH S | Director | Jun 29 '26 | Sale | 34.55 | 800,000 | 27,642,000 | 13,701,546 | Jun 30 |
| QVT Financial LP | other: Director by Deputization | Jun 26 '26 | Sale | 34.00 | 625,783 | 21,275,309 | 14,501,546 | Jun 30 |
| MANCHESTER KEITH S | Director | Jun 26 '26 | Sale | 34.00 | 625,783 | 21,275,309 | 14,501,546 | Jun 30 |
| Gold Daniel Allen | Director | Jun 26 '26 | Sale | 34.00 | 625,783 | 21,275,309 | 14,501,546 | Jun 30 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.